KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $56.1 million.

  • Emergent BioSolutions' Accumulated Expenses fell 42.18% to $36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.6 million, marking a year-over-year decrease of 42.18%. This contributed to the annual value of $56.1 million for FY2024, which is 24.29% down from last year.
  • Emergent BioSolutions' Accumulated Expenses amounted to $56.1 million in FY2024, which was down 24.29% from $74.1 million recorded in FY2023.
  • Emergent BioSolutions' Accumulated Expenses' 5-year high stood at $88.7 million during FY2021, with a 5-year trough of $56.1 million in FY2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $74.1 million (2023), whereas its average is $72.5 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Accumulated Expenses soared by 35.58% in 2020, and later dropped by 24.29% in 2024.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Accumulated Expenses stood at $84.6 million in 2020, then climbed by 4.85% to $88.7 million in 2021, then declined by 1.58% to $87.3 million in 2022, then dropped by 15.12% to $74.1 million in 2023, then dropped by 24.29% to $56.1 million in 2024.